- Home
- RMTI vs DVAX Comparison
RMTI vs DVAX Comparison
Compare RMTI & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMTI | DVAX |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 1.3B |
| IPO Year | 1998 | 2004 |
Fundamental Metrics
Financial Performance| Metric | RMTI | DVAX |
|---|---|---|
| Price | $0.80 | $15.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | $2.50 | ★ $26.50 |
| AVG Volume (30 Days) | 235.6K | ★ 3.7M |
| Earning Date | 11-12-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $75,577,000.00 | ★ $330,514,000.00 |
| Revenue This Year | N/A | $24.63 |
| Revenue Next Year | $8.12 | $15.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 26.73 |
| 52 Week Low | $0.78 | $9.20 |
| 52 Week High | $2.41 | $15.49 |
Technical Indicators
Market Signals| Indicator | RMTI | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 38.44 | 88.85 |
| Support Level | $0.80 | $10.78 |
| Resistance Level | $0.89 | $15.43 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | -0.00 | 0.51 |
| Stochastic Oscillator | 14.24 | 97.74 |
Price Performance
Historical ComparisonAbout RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.